transient receptor potential cation channel subfamily C member 1Genealiases: HTRP-1 · TRP1
Q-omics provides the consensus-scored TRPC1 profile across patient tissues and cancer cell-line models. TRPC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRPC1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, TRPC1 RNA expression shows 19,654 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, BLCA, and UVM as cancer lineages where TRPC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC1 survival associations across molecular data types. TRPC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC1 RNA expression–survival associations across cancer types. High TRPC1 expression shows unfavorable associations in UCEC, ACC, BLCA, MESO and LIHC, but favorable associations in SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TRPC1 RNA expression.
This table summarizes TRPC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRPC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC1 shows lower tumor expression in BLCA, THCA, COAD and UCEC and higher tumor expression in KIRC and KIRP. The BLCA box plot shows higher TRPC1 RNA expression in normal versus tumor tissue (log2 FC = −1.635, t-test p < 0.001).
This table shows molecular features associated with TRPC1 in patient tissues and cancer cell lines. In patient samples, TRPC1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
